Navigation Links
Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
Date:6/15/2013

use you are removing the target," said lead author Suzanne Wardell, PhD, a research scientist working in McDonnell's lab.

Many investigators had assumed that once breast cancer cells developed resistance to tamoxifen, they would be resistant to all drugs that target the estrogen receptor, McDonnell explained.

"We discovered that the estrogen receptor is still a good target, even after it resistance to tamoxifen has developed," he said.

The investigators tested a variety of breast cancer cell types, including tamoxifen-sensitive cells that are resistant to the drug lapatinib, another targeted therapy that is used to treat patients with advanced breast cancer whose tumors contain the mutant HER2 gene. These cells had previously been shown to reactivate estrogen signaling in order to acquire drug resistance. In this cell type, bazedoxifene also potently inhibited cell growth.

Paradoxically, in bone tissue, bazedoxifene mimics the action of estrogen, helping protect it from destruction. Because bazedoxifene has already undergone safety and efficacy studies as a treatment for osteoporosis, it may be a viable near-term option for patients with advanced breast cancer whose tumors have become resistant to other treatment options, Wardell reported. In clinical trials, the most often reported side effect was hot flashes in the bazedoxifene treatment groups.


'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-419-5069
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. IOF Worldwide Conference of Osteoporosis Patient Societies opens in Helsinki
2. Program announced for the 4th Asia-Pacific Osteoporosis Meeting in Hong Kong
3. Worlds largest meeting dedicated to osteoporosis and osteoarthritis opens in Rome
4. European Guidance for the diagnosis & management of osteoporosis in postmenopausal women
5. Less than 1 month to start of European Congress on Osteoporosis & Osteoarthritis in Rome
6. 4th Asia-Pacific Osteoporosis Meeting to be led by regions leading bone experts
7. European Congress on Osteoporosis and Osteoarthritis
8. Summit of osteoporosis experts from CIS countries issue 5-point call for action
9. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
10. Launch of the EU large-scale integrating project BlueGenics to combat osteoporosis
11. Register now for the key osteoporosis meeting in the Asia-Pacific region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ) ... Sensors Market Forecast and Opportunities 2020" report ... is projected to grow at a CAGR over ... industrial and healthcare sectors are the key application ... adoption of MEMS technology in sensors is growing ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... MINNETONKA, Minn. , March 17, 2015 /PRNewswire/ ... sciences technology company specializing in clinical study management ... will be in attendance at ARENA,s Outsourcing in ... Cary, NC.  This event provides an excellent forum ... company,s easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... reliable indicators to predict that a person will develop type ... produced in the pancreas and is the hormone responsible for ... body, such as muscles. Insulin resistance is characterized by the ... a greater production of insulin by the pancreas. When the ...
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide provider of ... quarter of 2008. , Total ... $15.6 million for the third quarter of 2007. The decrease ... year ago was largely due,to lower revenues in the U.K. , ...
... ARLINGTON, Va., Nov. 18 Stanley, Inc.,(NYSE: ... professional,services to the U.S. federal government, today announced that ... International Corporation (NYSE: SAI ) awarded,a four-year, ... if,all three option years are exercised. With this award, ...
Cached Biology News:Researchers at IRB Barcelona produce more data on key genes in diabetes 2Researchers at IRB Barcelona produce more data on key genes in diabetes 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 2Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 3
(Date:4/1/2015)... 1, 2015 Emerson Ecologics is excited to ... of Better Medicine . The conference will provide integrative ... a thriving and fulfilling practice. Scheduled ... Resort and Spa, the conference will be a one-of-a-kind, ... accomplish key projects and leave with an action plan ...
(Date:4/1/2015)... TORONTO , April 1, 2015 /PRNewswire/ - ... Securities Exchange: PBT.U), is pleased to announce that ... holds 54% equity, has entered into an agreement ... Biohaven,s first clinical trial with their lead compound ... the identification and development of clinical stage neuroscience ...
(Date:4/1/2015)... /CNW/ - Canada,s Research-Based Pharmaceutical Companies ... released report on Cost Drivers of Public Drug Plans in ... the report, the rates of change in drug costs have ... -0.8 percent in 2012/13 for a number of select public ... the costs of medicines without considering their overall impact on ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 Holomic ... that can read both chromatographic and fluorescent rapid tests ... supplier of high performance, quantitative readers and is already ... The HRDR-400 is a first of its kind offering ... one instrument. , Dr. Neven Karlovac, CEO of ...
Breaking Biology Technology:Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3Rx&D responds to PMPRB report: overall impact of medicines must always be considered 2Holomic to Introduce the First Dual, Chromatographic and Fluorescent Rapid Test Reader, the HRDR-400 2
... Some of the first data from a new orbiting infrared ... analogy galaxies in general - is making new stars at ... findings from NASA's Spitzer Space Telescope were announced today (May ... a University of Wisconsin-Madison astronomer and the leader of a ...
... for 10 years in tax credits , ,MADISON ... Wisconsin was discussed at an economic development breakfast panel ... Business Development Center at the MG&E Innovation Center. A ... and private sector, discussed the implications of new tax-credit ...
... Formulatrix Inc. and Bruker AXS have ... incubation and imaging products. , ,Crystal Farm, developed by ... International , is an integrated product for incubation and ... design drugs. The system will now work with Formulatrixs ...
Cached Biology Technology:Milky Way churning out new stars at a furious pace 2Milky Way churning out new stars at a furious pace 3The impact of ACT 255 on the future of high-tech investment in Wisconsin 2Protein-crystal companies join forces for better imaging process 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
IHC detection kit for PCNA in cells and tissues...
Biology Products: